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Abstract
Objective: The present review addresses the relationship between sleep 
and depression and how serotonergic transmission is implicated in both 
conditions. Method: Literature searches were performed in the PubMed 
and MedLine databases up to March 2010. The terms searched were 
“insomnia”, “depression”, “sedative antidepressants” and “serotonin”. In 
order to pinpoint the sedative antidepressants most used to treat insomnia, 
34 ISI articles, mainly reviews and placebo-controlled clinical trials, were 
selected from 317 articles found in our primary search. Results: Sleep 
problems may appear months before the diagnosis of clinical depression 
and persist after the resolution of depression. Treatment of insomnia 
symptoms may improve this comorbid disease. Some antidepressant 
drugs can also result in insomnia or daytime sleepiness. Serotonin (5-HT) 
demonstrates a complex pattern with respect to sleep and wakefulness 
that is related to the array of 5-HT receptor subtypes involved in different 
physiological functions. It is now believed that 5HT
2
 receptor stimulation 
is subjacent to insomnia and changes in sleep organization related to 
the use of some antidepressants. Conclusion: Some drugs commonly 
prescribed for the treatment of depression may worsen insomnia and 
impair full recovery from depression. 5-HT
2
 receptor antagonists are 
promising drugs for treatment strategies since they can improve comorbid 
insomnia and depression.
Descriptors: Neurochemistry; Antidepressive agents; Sleep; Depressive 
disorder; Psychopharmacology
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Resumo
Objetivo: Esta atualização aborda a relação entre sono e depressão e como 
a transmissão serotoninérgica está envolvida em ambas condições. Método: 
Foi realizada uma busca na literatura no PubMed e MedLine até março 
de 2010 com os termos “insônia”, “depressão”, “antidepressivos sedativos” e 
“serotonina”. A fim de contemplar os antidepressivos sedativos mais utilizados 
no tratamento da insônia, 34 artigos ISI, principalmente revisões e estudos 
clínicos placebo-controlados, foram selecionados entre 317 artigos encontrados 
na busca inicial. Resultados: Alterações de sono podem aparecer meses antes 
do diagnóstico clínico de depressão e persistir após a resolução da depressão. 
O tratamento dos sintomas de insônia pode melhorar essa doença associada. 
Alguns antidepressivos também podem levar à insônia ou sonolência diurna. A 
serotonina (5-HT) demonstra um padrão complexo no que diz respeito ao sono 
e vigília, o que está relacionado com a variedade de subtipos do receptor 5-HT 
envolvidos em diferentes funções fisiológicas. Acredita-se, atualmente, que a 
estimulação do receptor 5-HT2 esteja envolvida nas alterações da organização 
do sono e insônia relacionada a alguns antidepressivos. Conclusão: Alguns 
medicamentos normalmente prescritos para o tratamento de depressão 
podem piorar a insônia e dificultar a completa recuperação da depressão. Os 
antagonistas do receptor 5-HT2 são drogas promissoras para o tratamento, 
pois podem melhorar a insônia e depressão associadas.
Descritores: Neuroquímica; Antidepressivos; Sono; Transtorno depressivo; 
Psicofarmacologia
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Introduction
Sleep disorders have been reported as symptoms seen in many 
depressed patients.1 Insomnia may occur in 60-80% of patients 
with major depressive disorder and hypersomnia in approximately 
15-20%.2 Depressive symptoms are important risk factors for 
insomnia, and depression is considered an important comorbid 
condition in patients with chronic insomnia of any etiology.3 
Insomnia and sleepiness may also occur as side effects of some 
antidepressant drugs.4 
Different models have been proposed to explain changes in 
sleep patterns associated with depression. Process S, for instance, 
refers to the quantitative need for sleep that builds up while a 
person is awake and declines during sleep, and is dependent on 
how long a person is awake and on how active they are while 
awake. The deficiency theory states that Process S in depressive 
patients is deficient in the waking state, which is reflected in 
reduced delta activity. Some authors have described how the delta 
ratio (delta sleep duration from the first to the second rapid eye 
movement – REM – period) is reduced in depressive patients.5-7 
Another model is based on experimental evidence on the reciprocal 
interaction between cholinergic REM-on and aminergic REM-
off neurons.5,6 REM-suppressive antidepressant therapy supports 
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this model. Cholinergic/aminergic interaction is subject to both 
ultradian and circadian cycles. The internal coincidence model 
supposes that there is a strong circadian oscillator controlling REM 
sleep and a weak oscillator controlling the wake–sleep cycle.5 In 
depressive patients the strong oscillator is in the advanced phase, 
causing them to sleep late in relation to the biological clock.5 
The activation model5 suggests that depressive patients present 
altered regulation of cortical activation, so that they tend to 
remain in a hyper-activated state during wakefulness. If, on one 
hand, brain imaging of glucose metabolism supports the hyper-
activation theory, on the other hand, clinical evidence shows that 
hypo-activation symptoms are frequent and that unidimensional 
models are inadequate.5 
Method
This is an updated report which focuses on the relationship 
between sleep, insomnia, 5HT and depression, with particular 
attention to sedative antidepressants in the context of insomnia. 
Other effects of antidepressants, with the exception of sedation, 
are beyond the scope of this report. For concision, we included 
the most commonly prescribed compounds of this class, which 
included: trazodone, mirtazapine, agomelatine and doxepine 
Literature searches were performed in the PubMed and MedLine 
databases up to March 2010. The terms searched were “insomnia”, 
“depression”, “sedative antidepressants“ and “serotonin“. We 
started with 317 references and have given priority to reviews 
(15), randomized placebo-controlled studies and other controlled 
studies (11), but also included update articles (2), cohort 
and epidemiological studies (4), an open label study (1) and 
experimental data in humans and animals (3). Case reports and 
articles assessing other sedative-hypnotic substances were excluded. 
A total of 34 references were included. 
Among reviews and controlled studies we have included about 
three articles for each of the mentioned sedative antidepressants. 
The relationship between sleep and depression 
Depressive symptoms are the greatest and most consistent risk 
factors for insomnia, which is often the presenting symptom in 
the depressed patient seeking help.5 Sleep problems may appear 
months before the diagnosis of clinical depression and persist after 
its resolution; treatment of insomnia symptoms may improve this 
comorbid disease. In fact, patients with chronic insomnia, lasting 
for many years, present significant scores in depression scales even 
when DSM-IV criteria for major depression are not fulfilled.8 Data 
indicate that insomnia can precede episodes of depression by 5 
weeks.9 Treating insomnia may prevent or shorten the period of 
depression. Symptoms related to insomnia may also be related 
to depression.  
Sleep duration is believed to be particularly important in 
predicting manic and depressive symptoms. Sleep deprivation 
was associated with temporary remission of depressive symptoms. 
Insomnia was classified in a study as onset, maintenance, mixed 
(no onset or maintenance disturbance) and combined (both 
onset and maintenance disturbance).10 Patients with the latter 
type had higher Beck Depression Inventory scores,10 indicating 
that patients with persistent insomnia were 1.8-3.5 times more 
likely to remain depressed, compared with patients with no 
insomnia.10 This suggests that in addition to being a risk factor 
for depressive episodes, persistent insomnia perpetuates the illness 
in some elderly patients.11 Consequently, managing insomnia may 
enhance the treatment outcome of this comorbid disease.8 There is 
a dearth of clinical trials examining the effectiveness of hypnotics 
in the treatment of depression associated with insomnia. Some 
studies show that relief of sleep disturbance is often determinant 
of compliance with antidepressant treatment. 
To date there have been few studies evaluating the efficacy of 
antidepressant drugs in primary insomnia.1 A randomized trial 
compared the efficacy of trazodone therapy to zolpidem therapy 
and placebo for patients with primary insomnia.12 Compared 
to zolpidem, trazodone was less effective in improving sleep 
disturbances in those patients.12 Despite the widespread use of 
trazodone for insomnia, there are limited data available, most of 
them on insomnia associated with depression.12 More studies are 
needed on the effect and long-term safety of trazodone in primary 
insomnia and in the elderly, among whom its use is frequent. A 
randomized crossover study, using polysomnography and patient 
reporting, evaluated doxepin therapy for adults with primary 
insomnia,1,13 and has shown its efficacy in improving sleep.13 
Trimipramine and paroxetine were also analyzed, but results were 
not promising.1 Thus, there is no evidence that antidepressants 
are superior to the new nonbenzodiazepine hypnotics to treat 
primary insomnia.
Selective serotonin reuptake inhibitors and their 
impact on sleep 
The most common sleep disturbances in depressed patients, as 
documented in visually-scored polysomnograms, include:
1) Altered duration and sustenance of sleep. Total sleep time is 
reduced, due to an increase in sleep latency and wake time after 
sleep onset (WASO), and early morning awakening. However, 
15-20% present hypersomnia.5,14 Depressive individuals frequently 
show sleep-stage changes and a higher arousability. Sleep quality 
is reduced due to sleep fragmentation. 
2) Reduced REM sleep latency, increment of first REM period, 
increased REM sleep in the first third of the night and reduced 
REM sleep in the latter. Increased REM density during the first 
third of the night.5,14 
3) Reduced slow-wave sleep (SWS) duration and proportion. 
Spectral analysis studies show reduced slow-wave activity during 
non-REM sleep, especially in the first period.5,14
The most persistent polysomnographic alterations in depressed 
patients are a reduction in the amount of slow-wave sleep and 
reduced REM-sleep latency.15 
Research suggests that the same neurotransmitter systems 
that regulate mood, motivation and energy can be abnormally 
regulated in depression and contribute to sleep disturbance.1,4 
Some neurotransmitter systems have been implicated in the 
maintenance of wakefulness, the initiation and maintenance of 
Serotonin pattern with respect to sleep
Revista Brasileira de Psiquiatria 2011 • vol 33 • nº 1 • mar2011 • 93
sleep and the transitions, within sleep, from one state to another.1 
The currently approved antidepressant drugs exert effects on one 
or several of these neurotransmitter systems, so it is not surprising 
that the antidepressant drugs produce diverse effects on sleep 
and wakefulness.1,16-18 Tricyclic antidepressants block presynaptic 
reuptake of norepinephrine and 5-HT (serotonin).1,17,18 Some are 
more selective for norepinephrine (desipramine, protriptyline) 
increasing awakenings and reducing total sleep time.1,17-19 Others 
preferentially act upon 5-HT (clomipramine, amitriptyline, 
doxepin) inducing sleep and daytime somnolence.1,16-18 Tricyclic 
antidepressants  have other effects on neurotransmitter systems, 




 andrenergic and 
muscarinic cholinergic receptors, and may lead to daytime 
sleepiness.1,17-19 Tricyclics also produce potent REM sleep 
suppression. Inhibitors of the enzyme monoamine oxidase 
enhance monoamine neurotransmission by increasing presynaptic 
concentrations of norepinephrin, dopamine and 5-HT.1,16-19 This 
catecholaminergic stimulation may disrupt sleep continuity.1 By 
increasing monoaminergic transmission, REM sleep muscle tonus 
regulation may be disturbed in rare cases, inducing episodes of 
REM sleep behavior disorder.20
Serotonin demonstrates a more complex pattern with respect 
to sleep and wakefulness that is related to the array of 5-HT 
receptor subtypes involved in different physiological functions. 
Serotonergic neurons play a vital role in the modulation of 
the onset and maintenance of sleep, and sleep disturbance in 
depression is linked to alterations of serotonergic pathways.1,4 
Depressed individuals treated with serotonin reuptake inhibitors 
(SSRIs) often complain of persistent sleep disturbances such as 
insomnia and daytime somnolence.4 Corroborating the clinical 
data, polysomnography often demonstrates that SSRI therapy 
is associated with greater fragmentation of sleep, suppression 
of REM sleep, prolonged sleep latency and reduced total sleep 
time.1 Insomnia during the use of fluoxetine represented one 
of the most common side effects.1 Paradoxically, daytime 
somnolence has also frequently been reported.1,18 Fluoxetine has 
been shown to reduce REM sleep.1,17,18 Polysomnographic studies 
showed that paroxetine, sertraline, citalopram and escitalopram 
presented similar adverse effects on sleep although these were 
less pronounced.1,17,18 Disruption of sleep continuity appears to 
be a dose-dependent effect of the SSRIs.1 They cause insomnia 
in 10-20% of depressed patients due to the suppression of REM 
sleep.1,17,18
Pharmacological studies have implicated serotonin as a promoter 
of sleep. In experimental conditions, the blocking of 5-HT 
synthesis caused long-lasting insomnia.21 However, stimulation 
of the dorsal raphe nucleus of cats elicits arousal.21 Stimulation 
during REM sleep suppresses ponto-geniculooccipital waves 
associated with REM sleep.21 5-HT receptors have a complex role 












 have an inhibitory action 
on REM sleep. 
Some antidepressants, especially 5-HT
2
 antagonists, have 
beneficial effects by increasing SWS duration, sparing REM 
sleep.1,17,18 The precursors of 5-HT biosynthesis, L-tryptophan 
and 5-hydrosytryptophan, have promoted the onset of sleep.1,21 
Depletion of 5-HT by reserpine produces states of profound 





 are closely related to alertness. 5-HT
2
 receptors (A, B and 
C subtypes) activate phospholipase C, and can be considered 
excitatory.21 5-HT
1A
 receptor agonists decrease REM sleep 
duration and sleep fragmentation.17,22,23 5-HT
2A
 receptors are 
found in the cortex and basal ganglia, mediate certain behavioral 
syndromes and are implicated in the pathophysiology of 
psychiatric disorders associated with sleep disturbances such as 
depression and psychosis.21 It is believed that 5HT
2
 receptor 
stimulation is subjacent to insomnia and to sleep architecture 
alterations related to SSRIs.1 For this reason, 5HT
2
 blockers, 
like trazodone, improve insomnia and ameliorate sleep structure. 
5HT
2
-blocker antidepressants are a good option to treat insomniac 
depressive patients.17 Polysomnography in patients treated with 
trazodone showed increased slow-wave sleep (SWS) during the 
first half of the night by intensifying the mechanism that generates 
it.24 Long-term treatment showed increased sleep duration in 
stage 2, reduced sleep latency, increased delta sleep, and reduced 
REM latency.1,25 
Treatment of comorbid insomnia and depression
Successful treatment of patients with comorbid insomnia and 
depression requires attention to both conditions.26 Depressed 
patients with sleep disturbances have a significantly worse 
prognosis in relation to remission rates and the likelihood 
of complete and sustained recovery.26 Continued insomnia 
following antidepressant therapy is related to risk of relapse.26 
In a longitudinal study, two-thirds of patients with persistent 
insomnia at the end of treatment with antidepressants and 
psychotherapy relapsed within one year after switching to a 
placebo.27 On the other hand, 90% of patients with good sleep 
patterns remained well during the first year after discontinuing 
antidepressants.27 There is some evidence that insomnia may be the 
first prodromal symptom in previously remitted patients.27 When 
sleep disturbances become associated with distress and impairment 
of functioning in significant domains, and criteria for the diagnosis 
of insomnia are met, then insomnia is no longer a symptom 
of depression but a comorbid disorder that may impair the 
response to antidepressants.26 The majority of currently available 
antidepressants and hypnotic medications do not improve 
SWS, a target for improving depression and insomnia.1 Some 
antidepressants such as trazodone and nefazodone are effective 
in restructuring sleep architecture and are potentially options for 
simultaneously reducing depression and insomnia.1,4 Trazodone 







receptors, which may contribute to its sleep-promoting 
properties. It also produces inhibitory effects at the presynaptic 
5-HT reuptake site. The combination of weak inhibition of 5-HT 
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blockade of 5-HT
2 
receptors with other pharmacological targets: 
agomelatin, a melatonin receptor agonist and 5-HT
2 
antagonist 
has effective antidepressant and hypnotic activity.29-31 
Conclusion
Present knowledge suggests that some neurotransmitter systems 
are simultaneously implicated in mood disorders and sleep 
disturbances.1,4 Deeper non-REM sleep (SWS) is very important 
for maintaining homeostasis1,32 and is related to restorative sleep 
and well-being.1,32 Some drugs prescribed for the treatment 
of depression may worsen insomnia and impair full recovery 
from depression.1,4 Thus, new drugs have been developed that 
may be able to manage depression and insomnia symptoms 
simultaneously.1,4,18,33 5-HT
2
 receptor antagonists are promising 
drugs for treatment strategies since they can improve comorbid 
insomnia and depression.1,27,33 Future research is needed to address 
the simultaneous treatment of insomnia and mood disorders to 
foster a better treatment outcome and to address the long-term 
safety and efficacy of 5HT
2
 antagonists in the treatment of 
primary insomnia.
In addition, future studies to uncover the neurobiology that is 
thought to underlie insomnia and depression are needed.34
reuptake and blockade of 5-HT
2 
receptors explains the fact that 
trazodone enhances SWS and causes minimal, if any, suppression 
of REM sleep. Trazodone also inhibits alpha-1 adrenoreceptors 
and, slightly, histamine H
1
 receptors, contributing to promotion 
of sleep.1,24 Nefazodone exerts weak 5-HT presynaptic reuptake 
inhibition together with blockade of 5-HT
2
 receptors, preserving 
sleep architecture and REM sleep. Bupropion is associated with 
insomnia in some cases.1 In contrast with most antidepressants, 
bupropion increases REM sleep. Bupropion blocks presynaptic 
reuptake of dopamine and norepinephrin,1 although it modestly 
enhances catecholamine neurotransmission. Mirtazapine 
demonstrates potent sleep-promoting effects by inhibiting the 
presynaptic alpha-2 autoreceptors, which increases norepinephrin 





receptors, and blocking histamine-H1 receptors.  
Agents that selectively target 5-HT
2
 hold great promise for the 
treatment of the comorbid conditions. Studies have shown that 
Ritanserin, a potent 5-HT
2
 antagonist, significantly improved 
SWS and sleep quality in major depression. Another study on 
ritanserin in narcolepsy showed improved sleep quality and 
reduced daytime sleepiness.28 Other selective drugs are under 
development: eplivanserin and volinanserin. Some drugs combine 
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